Literature DB >> 17458501

Drugs of the future: the hormone relaxin.

C S Samuel1, T D Hewitson, E N Unemori, M L-K Tang.   

Abstract

The peptide hormone relaxin is emerging as a multi-functional factor in a broad range of target tissues including several non-reproductive organs, in addition to its historical role as a hormone of pregnancy. This review discusses the evidence that collectively demonstrates the many diverse and vital roles of relaxin: the homeostatic role of endogenous relaxin in mammalian pregnancy and ageing; its gender-related effects; the therapeutic effects of relaxin in the treatment of fibrosis, inflammation, cardioprotection, vasodilation and wound healing (angiogenesis) amongst other pathophysiological conditions, and its potential mechanism of action. Furthermore, translational issues using experimental models (to humans) and its use in various clinical trials, are described, each with important lessons for the design of future trials involving relaxin. The diverse physiological and pathological roles for relaxin have led to the search for its significance in humans and highlight its potential as a drug of the future.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17458501     DOI: 10.1007/s00018-007-6543-y

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  24 in total

1.  Gene duplication and positive selection explains unusual physiological roles of the relaxin gene in the European rabbit.

Authors:  José Ignacio Arroyo; Federico G Hoffmann; Juan C Opazo
Journal:  J Mol Evol       Date:  2012-02-22       Impact factor: 2.395

Review 2.  The emerging role of relaxin as a novel therapeutic pathway in the treatment of chronic kidney disease.

Authors:  Jennifer M Sasser
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2013-07-24       Impact factor: 3.619

Review 3.  Relaxin and fibrosis: Emerging targets, challenges, and future directions.

Authors:  Anthony J Kanai; Elisa M Konieczko; Robert G Bennett; Chrishan S Samuel; Simon G Royce
Journal:  Mol Cell Endocrinol       Date:  2019-02-14       Impact factor: 4.102

Review 4.  Serelaxin in clinical development: past, present and future.

Authors:  Elaine Unemori
Journal:  Br J Pharmacol       Date:  2017-01-29       Impact factor: 8.739

5.  Therapeutic effects of a small molecule agonist of the relaxin receptor ML290 in liver fibrosis.

Authors:  Elena M Kaftanovskaya; Hooi Hooi Ng; Mariluz Soula; Bryan Rivas; Courtney Myhr; Brian A Ho; Briana A Cervantes; Thomas D Shupe; Mahesh Devarasetty; Xin Hu; Xin Xu; Samarjit Patnaik; Kenneth J Wilson; Elena Barnaeva; Marc Ferrer; Noel T Southall; Juan J Marugan; Colin E Bishop; Irina U Agoulnik; Alexander I Agoulnik
Journal:  FASEB J       Date:  2019-08-16       Impact factor: 5.191

6.  Controlled extracellular matrix degradation in breast cancer tumors improves therapy by trastuzumab.

Authors:  Ines Beyer; Zongyi Li; Jonas Persson; Ying Liu; Ruan van Rensburg; Roma Yumul; Xiao-Bing Zhang; Mien-Chie Hung; André Lieber
Journal:  Mol Ther       Date:  2010-11-16       Impact factor: 11.454

Review 7.  Relaxin: review of biology and potential role in treating heart failure.

Authors:  Sam L Teichman; Elaine Unemori; John R Teerlink; Gad Cotter; Marco Metra
Journal:  Curr Heart Fail Rep       Date:  2010-06

8.  Toward a stem cell gene therapy for breast cancer.

Authors:  ZongYi Li; Ying Liu; Sebastian Tuve; Ye Xun; Xiaolong Fan; Liang Min; Qinghua Feng; Nancy Kiviat; Hans-Peter Kiem; Mary Leonora Disis; André Lieber
Journal:  Blood       Date:  2009-03-27       Impact factor: 22.113

9.  In vivo imaging of extracellular matrix remodeling by tumor-associated fibroblasts.

Authors:  Jean Y Perentes; Trevor D McKee; Carsten D Ley; Hannah Mathiew; Michelle Dawson; Timothy P Padera; Lance L Munn; Rakesh K Jain; Yves Boucher
Journal:  Nat Methods       Date:  2009-01-18       Impact factor: 28.547

10.  Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trial.

Authors:  Dinesh Khanna; Philip J Clements; Daniel E Furst; Joseph H Korn; Michael Ellman; Naomi Rothfield; Fredrick M Wigley; Larry W Moreland; Richard Silver; Youn H Kim; Virginia D Steen; Gary S Firestein; Arthur F Kavanaugh; Michael Weisman; Maureen D Mayes; David Collier; Mary E Csuka; Robert Simms; Peter A Merkel; Thomas A Medsger; Martin E Sanders; Paul Maranian; James R Seibold
Journal:  Arthritis Rheum       Date:  2009-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.